Type
|
Public |
---|---|
Traded as | NYSE: BCR S&P 500 Component |
Founded | 1907 |
Founder | Charles Russell Bard |
Headquarters | New Providence, New Jersey, U.S. |
Area served
|
Worldwide |
Key people
|
Timothy M. Ring (Chairman) & (CEO) |
Products | Vascular, Urology, Oncology, and Surgical Specialties |
Revenue | US$2.72B (FY 2010) |
Operating income
|
US$730M (FY 2010) |
Net income
|
US$509M (FY 2010) |
Total assets | US$3.17B (FY 2010) |
Total equity | US$1.63B (FY 2010) |
Number of employees
|
14,000 (2015) |
Website | www |
C. R. Bard, Inc., now branded simply as Bard, headquartered in Murray Hill, New Jersey, USA, is a leading multinational developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties.
In April 2017, the company has announced that it will be acquired by Becton Dickinson.
Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. An S&P 500 company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the Foley catheter in 1934. In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company.
C. R. Bard, Inc. was founded in New York City by Charles R. Bard in 1907. Bard's first business involved importing Gomenol, which was used to treat urinary discomfort. The company formally incorporated in 1923, and three years later, in 1926, Charles R. Bard sold the company to John F. Willits and Edson L. Outwin for $18,000. Under Willits and Outwins, the company expanded into the catheter business, introducing the Foley catheter in 1934 and the America Woven Catheter in 1940.
In 1948, Bard's annual sales topped $1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, a Bard scientist, Dr. DeBakey, developed the first arterial prosthesis. Three years later the company began selling Foley catheters that came in sterile packaging for the first time ever. Bard continued to innovate in the world of catheters, rolling out the Bipolar Temporary Pacing catheter in 1958 and the first latex balloon catheter in 1960. In 1961, Bard expanded beyond catheters, and began manufacturing products related to cardiology, radiology, and anesthesiology.
Bard went public in 1963 and was listed on the New York Stock Exchange in 1968. The company has introduced a variety of new health care products since that time. Its net sales first exceeded $1 billion in 1994. Around 2012, Bard acquired the company Lutonix.
On April 23, 2017, it was announced that Bard would be bought by Becton Dickinson for $24 billion.
Bard specializes in the manufacturing of vascular, urology, oncology and surgical specialty products.
In 2013, Bard agreed to pay $48.26 million to resolve kickback allegations filed against the company, relating to submitting false claims to Medicare. The complaint, filed in 2006, alleges Bard paid illegal kickbacks to both physicians and consumers.
Vaginal mesh devices are threaded into the vagina to treat incontinence or to fortify pelvic muscles. Some women have charged that the devices "are poorly designed and contain materials that are unsafe for use in humans [and that] some require multiple surgeries to remove." In 2012 the U.S. Food and Drug Administration requested that Bard and other vaginal-mesh makers study rates of organ damage linked to the mesh devices. In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company. In August 2015 it was announced that Bard had agreed to pay more than $200 million to resolve at least 3,000 of the legal cases related to the devices. The settlement resolves about one-fifth of the outstanding suits related to the implants. Bard said in court filings its devices are "safe and effective."
An Inferior vena cava filter, or more simply, a blood clot filter, is a device that is surgically placed in the vena cava artery to prevent blood clots from moving into the heart or lungs, which can be fatal. On December 31, 2015, NBC News released information about an investigation that they had conducted of the Bard G2 series filters which had replaced an earlier version, the Recovery filter. Introduced in 2002, the Recovery filter was associated with 27 deaths and several hundred non-fatal problems, and "a confidential study commissioned by Bard showed that the Recovery filter had higher rates of relative risk for death, filter fracture and movement than all of its competitors." However, according to the NBC report, the G2 series filters were a modified version of the Recovery filter and Bard was aware that it had "similar and potentially fatal flaws" shortly after it was put on the market. But instead of recalling the replacement filters, they were kept on the market for five years. According to Bard and FDA records, at least 12 deaths and hundreds of problems have been linked to the G2 series filters.
2016-07-08 | Downgrade | Bank of America Corp. | Buy to Neutral | |
2016-05-25 | Reiterated Rating | Leerink Swann | Hold | |
2016-05-24 | Boost Price Target | Barclays | Equal Weight | $212.00 to $224.00 |
2016-05-24 | Reiterated Rating | Piper Jaffray | Buy | $241.00 |
2016-05-24 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-05-24 | Reiterated Rating | Piper Jaffray Cos. | Buy | $241.00 |
2016-05-24 | Boost Price Target | Barclays PLC | Equal Weight | $212.00 to $224.00 |
2016-05-23 | Reiterated Rating | Bank of America | Buy | |
2016-05-23 | Reiterated Rating | Bank of America Corp. | Buy | |
2016-05-22 | Reiterated Rating | Morgan Stanley | Hold | |
2016-04-28 | Boost Price Target | Barclays | Equal Weight | $195.00 to $212.00 |
2016-04-28 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-03-30 | Boost Price Target | Leerink Swann | Market Perform | $196.00 to $205.00 |
2016-03-17 | Initiated Coverage | Nomura | Neutral | $205.00 |
2016-03-17 | Initiated Coverage | Nomura Holdings Inc. | Neutral | $205.00 |
2016-02-10 | Reiterated Rating | Deutsche Bank | Hold | |
2016-02-10 | Reiterated Rating | Deutsche Bank AG | Hold | |
2016-01-31 | Reiterated Rating | Deutsche Bank | Hold | |
2016-01-29 | Lower Price Target | Goldman Sachs | Buy | $214.00 to $211.00 |
2016-01-29 | Lower Price Target | Goldman Sachs Group Inc. | Buy | $214.00 to $211.00 |
2016-01-27 | Boost Price Target | JMP Securities | Market Outperform | $207.00 to $215.00 |
2015-11-12 | Initiated Coverage | Citigroup Inc. | Buy | $220.00 |
2015-10-23 | Reiterated Rating | Brean Capital | Hold | |
2015-10-23 | Reiterated Rating | William Blair | Hold | |
2015-10-23 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-10-23 | Lower Price Target | Leerink Swann | Market Perform | $192.00 to $190.00 |
2015-10-23 | Lower Price Target | JMP Securities | Market Outperform | $220.00 to $207.00 |
2015-09-10 | Boost Price Target | JMP Securities | Market Outperform | $200.00 to $220.00 |
2015-08-27 | Initiated Coverage | KeyBanc | Sector Weight | |
2015-08-27 | Upgrade | Goldman Sachs | Neutral to Buy | $193.00 to $220.00 |
2015-08-27 | Initiated Coverage | KeyCorp | Sector Weight | |
2015-07-23 | Reiterated Rating | Brean Capital | Hold | |
2015-04-26 | Reiterated Rating | Brean Capital | Hold | |
2015-04-24 | Boost Price Target | Barclays | Equal Weight | $175.00 to $185.00 |
2015-04-24 | Upgrade | Bank of America | Underperform to Buy | $200.00 |
2015-01-30 | Reiterated Rating | Jefferies Group | Hold | $145.00 to $170.00 |
2015-01-30 | Boost Price Target | Barclays | Equal Weight | $150.00 to $175.00 |
2015-01-30 | Boost Price Target | JMP Securities | Market Outperform | $162.00 to $186.00 |
2015-01-30 | Reiterated Rating | Brean Capital | Hold | |
2015-01-20 | Upgrade | JPMorgan Chase & Co. | Underweight to Neutral | $162.00 to $178.00 |
2015-01-05 | Downgrade | JPMorgan Chase & Co. | Neutral to Underweight | $156.00 to $162.00 |
2015-01-05 | Upgrade | Morgan Stanley | Underweight to Equal Weight | $187.00 |
2014-12-22 | Initiated Coverage | Wells Fargo & Co. | Market Perform | |
2014-12-22 | Initiated Coverage | Wells Fargo | Market Perform | |
2014-07-29 | Downgrade | Bank of America | Neutral to Underperform | $150.00 |
2014-07-25 | Reiterated Rating | Raymond James | Outperform | $155.00 to $170.00 |
2014-07-25 | Reiterated Rating | Jefferies Group | Hold | $139.00 to $145.00 |
2014-07-25 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $142.00 to $156.00 |
2014-07-25 | Reiterated Rating | Citigroup Inc. | Neutral | $147.00 to $153.00 |
2014-07-25 | Reiterated Rating | Raymond James Financial Inc. | Outperform | $155.00 to $170.00 |
2014-06-20 | Downgrade | S&P Equity Research | Buy to Hold | $145.00 to $150.00 |
2014-06-18 | Downgrade | Barclays | Overweight to Equal Weight | $155.00 to $150.00 |
2014-06-13 | Reiterated Rating | Deutsche Bank | Hold | $138.00 to $146.00 |
2014-06-03 | Reiterated Rating | Morgan Stanley | Positive to Underweight | $120.00 to $127.00 |
2014-04-07 | Downgrade | Bank of America | Buy to Neutral | $150.00 |
2014-03-10 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-03-06 | Boost Price Target | Barclays | Overweight | $150.00 to $160.00 |
2014-02-24 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-01-09 | Boost Price Target | Barclays | Overweight | $140.00 to $150.00 |
2014-01-08 | Upgrade | Atlantic Securities | Neutral to Overweight | $118.00 to $148.00 |
2014-01-06 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $142.00 |
2013-11-01 | Boost Price Target | Raymond James | Outperform | $140.00 to $150.00 |
2013-10-23 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $126.00 to $142.00 |
2013-10-23 | Boost Price Target | JMP Securities | Market Outperform | $130.00 to $140.00 |
2013-10-23 | Boost Price Target | Jefferies Group | Hold | $105.00 to $136.00 |
2013-10-23 | Boost Price Target | Cowen and Company | Market Perform | $102.00 to $123.00 |
2013-10-23 | Boost Price Target | BMO Capital Markets | Market Perform | $115.00 to $122.00 |
2013-10-23 | Boost Price Target | Barclays | Overweight | $135.00 to $140.00 |
2013-10-23 | Upgrade | Piper Jaffray | Neutral to Overweight | $114.00 to $140.00 |
2013-10-23 | Upgrade | Goldman Sachs | Sell to Neutral | $106.00 to $132.00 |
2013-10-14 | Reiterated Rating | Citigroup Inc. | Neutral | $123.00 to $124.00 |
2012-10-24 | Reiterated | Mizuho | Neutral | $93 to $88 |
2012-02-23 | Initiated | Northland Securities | Market Perform | $105 |
2011-09-16 | Initiated | Rodman & Renshaw | Mkt Perform | |
2011-02-01 | Downgrade | Morgan Joseph | Buy to Hold |
2016-07-08 | Downgrade | Bank of America Corp. | Buy to Neutral | |
2016-05-25 | Reiterated Rating | Leerink Swann | Hold | |
2016-05-24 | Boost Price Target | Barclays | Equal Weight | $212.00 to $224.00 |
2016-05-24 | Reiterated Rating | Piper Jaffray | Buy | $241.00 |
2016-05-24 | Reiterated Rating | Needham & Company LLC | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In BCR 45 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Institutional Trust Company, N.A. | 2.60M |
BlackRock Fund Advisors | 2.10M |
BlackRock Group LTD | 1.11M |
Standard Life Investments LTD | 0.63M |
BLACKROCK ADVISORS LLC | 0.63M |
JANUS CAPITAL MANAGEMENT LLC | 0.34M |
RUSSELL FRANK CO/ | 0.23M |
BlackRock Investment Management, LLC | 0.19M |
EverPoint Asset Management, LLC | 0.15M |
BlackRock Japan Co. Ltd | 0.13M |
MANAGED ACCOUNT ADVISORS LLC | 0.12M |
BAIRD ROBERT W & CO INC /WI/ | 63113 |
Airain ltd | 46007 |
ACADIA TRUST NA | 43352 |
CATAPULT CAPITAL MANAGEMENT LLC | 15537 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
DOLCH GARY D Sr. VP-Quality and Reg Affairs | 0.04% (27466) | BCR / |
KELLY BRONWEN K VP - Human Resources | 0.03% (24704) | BCR / |
BRESLAWSKY MARC C | 0.02% (12655) | BCO / BCR / |
Christian Patricia G VP -Quality, Reg & Med Affairs | 0.01% (9239) | BCR / |